Infinity Financial Statements From 2010 to 2021

INFI -  USA Stock  

USD 2.29  0.20  9.57%

Infinity Pharmaceuti financial statements provide useful quarterly and yearly information to potential Infinity Pharmaceuti investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Infinity Pharmaceuti financial statements helps investors assess Infinity Pharmaceuti's valuation, profitability, and current liquidity needs.
We have found ninety-seven available fundamental trends for Infinity Pharmaceuti, which can be analyzed and compared to other ratios and to its competitors. Please verify all of Infinity Pharmaceuti regular fundamental drivers against the trend between 2010 and 2021 to make sure the company can sustain itself down the road.
Infinity Pharmaceuti Enterprise Value is most likely to decrease significantly in the upcoming years. The preceding year's Enterprise Value was reported at 119.15 Million. The current Invested Capital is estimated to increase to about 1.1 M, while Net Income Per Employee is projected to decrease to (1.9 M).

Infinity Financial Statements 

 
Refresh
Check Infinity Pharmaceuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Infinity main balance sheet or income statement drivers, such as Gross Profit of 1.8 M, Interest Expense of 2.3 M or Operating Expenses of 63.4 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.27, PPandE Turnover of 0.91 or Receivables Turnover of 761. Infinity financial statements analysis is a perfect complement when working with Infinity Pharmaceuti Valuation or Volatility modules. It can also supplement various Infinity Pharmaceuti Technical models. Please see the analysis of Infinity Pharmaceuti Correlation against competitors.

Infinity Pharmaceuti Revenues

1.76 MillionShare

Infinity Pharmaceuti Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets40.4 M39.3 M153.9 M
Decreasing
Slightly volatile
Cash and Equivalents29.3 M28.6 M85.7 M
Decreasing
Stable
Investments5.8 M5.7 M53.1 M
Decreasing
Slightly volatile
Investments Current5.7 M5.5 M52.6 M
Decreasing
Slightly volatile
Investments Non Current169.3 K165 K550.3 K
Decreasing
Slightly volatile
Deferred Revenue169 K164.7 K47.9 M
Decreasing
Slightly volatile
Property Plant and Equipment Net3.2 M3.1 M8.2 M
Decreasing
Stable
Trade and Non Trade Receivables2.1 M2.1 M1.9 M
Increasing
Stable
Trade and Non Trade Payables4.4 MM6.5 M
Decreasing
Slightly volatile
Total Liabilities61.7 M62.3 M68.1 M
Decreasing
Stable
Shareholders Equity(23.6 M)(23 M)85.7 M
Decreasing
Slightly volatile
Accumulated Other Comprehensive Income(1 K)(1000)42.7 K
Decreasing
Slightly volatile
Current Assets37 M36 M142.7 M
Decreasing
Slightly volatile
Assets Non Current3.4 M3.3 M11.2 M
Decreasing
Slightly volatile
Current Liabilities16.8 M11 M25.3 M
Decreasing
Slightly volatile
Liabilities Non Current44.9 M51.3 M42.8 M
Decreasing
Stable
Total Debt1.5 M1.4 M15.6 M
Decreasing
Slightly volatile
Debt Current7.4 M6.9 M2.9 M
Increasing
Slightly volatile
Debt Non Current1.5 M1.4 M15.1 M
Decreasing
Slightly volatile
Shareholders Equity USD(23.6 M)(23 M)85.7 M
Decreasing
Slightly volatile
Cash and Equivalents USD29.3 M28.6 M85.7 M
Decreasing
Stable
Total Debt USD1.5 M1.4 M15.6 M
Decreasing
Slightly volatile
Accounts Payable3.7 MM3.8 M
Decreasing
Stable
Receivables856.7 K1.1 M986.6 K
Increasing
Slightly volatile

Infinity Pharmaceuti Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues1.8 M1.7 M58.6 M
Decreasing
Slightly volatile
Selling General and Administrative Expense16.9 M12.4 M24 M
Decreasing
Slightly volatile
Research and Development Expense27.5 M26.8 M84.2 M
Decreasing
Slightly volatile
Operating Expenses63.4 M40.2 M97.2 M
Decreasing
Slightly volatile
Interest Expense2.3 M2.4 MM
Decreasing
Stable
Income Tax Expense(67 K)(62.1 K)(109.2 K)
Decreasing
Very volatile
Weighted Average Shares58 M59.9 M46.7 M
Increasing
Slightly volatile
Weighted Average Shares Diluted58 M59.9 M46.7 M
Increasing
Slightly volatile
Revenues USD1.8 M1.7 M58.6 M
Decreasing
Slightly volatile
Gross Profit1.8 M1.7 M58.6 M
Decreasing
Slightly volatile

Infinity Pharmaceuti Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(46.4 K)(43 K)(1.4 M)
Increasing
Stable
Net Cash Flow Investment Acquisitions and Disposals13.1 M14.7 M9.5 M
Increasing
Very volatile
Net Cash Flow from Financing30.4 M27.4 M37.3 M
Decreasing
Stable
Issuance Repayment of Debt Securities (3.7 M)(3.6 M)6.9 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares8.1 M7.9 M27.8 M
Decreasing
Stable
Net Cash Flow from Investing12.3 M14.6 M8.3 M
Increasing
Very volatile
Net Cash Flow from Operations(38.6 M)(35.7 M)(44.3 M)
Increasing
Very volatile
Net Cash Flow or Change in Cash and Cash Equivalents6.8 M6.3 M1.5 M
Decreasing
Stable
Share Based Compensation1.5 M1.5 M7.5 M
Decreasing
Slightly volatile
Depreciation Amortization and Accretion495.7 K483 K1.5 M
Decreasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Average Equity3.443.191(0.0634)
Increasing
Slightly volatile
Gross Margin0.890.90.9829
Decreasing
Slightly volatile
Asset Turnover0.03690.0360.3199
Decreasing
Slightly volatile
Enterprise Value over EBITDA(3.42)(3.172)(11.6889)
Increasing
Stable
Sales per Share0.02980.0291.4756
Decreasing
Slightly volatile
Price to Sales Ratio79.6573.82119.7337
Increasing
Slightly volatile
Price to Book Value(6.07)(5.921)2.7825
Decreasing
Slightly volatile
Debt to Equity Ratio(2.78)(2.71)1.0228
Decreasing
Slightly volatile
Current Ratio4.413.2616.2345
Decreasing
Stable
Free Cash Flow per Share(0.65)(0.598)(1.0583)
Increasing
Stable
Book Value per Share(0.39)(0.384)2.1397
Decreasing
Slightly volatile
Tangible Assets Book Value per Share0.670.6573.773
Decreasing
Slightly volatile
Total Assets Per Share0.630.61133.4529
Decreasing
Slightly volatile
Cash Flow Per Share(0.6)(0.5556)(0.9442)
Increasing
Stable
Receivables Turnover761765836
Decreasing
Slightly volatile
PPandE Turnover0.910.8821.7924
Increasing
Very volatile
Cash and Equivalents Turnover0.06920.06740.9768
Decreasing
Slightly volatile
Accounts Payable Turnover0.770.744914.483
Decreasing
Slightly volatile
Accrued Expenses Turnover0.250.23774.0473
Decreasing
Slightly volatile
Long Term Debt to Equity0.270.270.5945
Decreasing
Slightly volatile
Quick Ratio2.462.39465.5221
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets76.4263.513874.4448
Decreasing
Very volatile
Revenue to Assets0.04490.04370.2915
Decreasing
Slightly volatile

Infinity Pharmaceuti Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization139.7 M136.1 M351.3 M
Decreasing
Slightly volatile
Enterprise Value122.3 M119.2 M285.6 M
Decreasing
Slightly volatile
Invested Capital1.1 M1.1 M50.7 M
Decreasing
Slightly volatile
Average Equity(13 M)(12.7 M)80.9 M
Decreasing
Slightly volatile
Average Assets49.3 M48 M146.1 M
Decreasing
Slightly volatile
Invested Capital Average13.6 M13.3 M59.9 M
Decreasing
Slightly volatile
Tangible Asset Value40.4 M39.3 M153.9 M
Decreasing
Slightly volatile
Free Cash Flow(38.6 M)(35.8 M)(45.5 M)
Increasing
Very volatile
Working Capital25.6 M25 M117.9 M
Decreasing
Slightly volatile
Revenue Per Employee76.5 K74.5 K470.4 K
Decreasing
Slightly volatile

Infinity Fundamental Market Drivers

Short Percent Of Float4.93%
Forward Price Earnings-3.75
Shares Short Prior Month5.77M
Average Daily Volume Last 10 Day1.11M
Average Daily Volume In Three Month1.6M
Date Short Interest29th of October 2021
Fifty Day Average2.7980
Two Hundred Day Average3.0477

Infinity Upcoming Events

Upcoming Quarterly Report15th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End15th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

About Infinity Pharmaceuti Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Infinity Pharmaceuti income statement, its balance sheet, and the statement of cash flows. Infinity Pharmaceuti investors use historical funamental indicators, such as Infinity Pharmaceuti's revenue or net income, to determine how well the company is positioned to perform in the future. Although Infinity Pharmaceuti investors may use each financial statement separately, they are all related. The changes in Infinity Pharmaceuti's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Infinity Pharmaceuti's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Infinity Pharmaceuti Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Infinity Pharmaceuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Deferred Revenue164.7 K169 K
Revenues1.7 M1.8 M
Revenue to Assets 0.043719  0.0449 
Revenue Per Employee74.5 K76.5 K
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 11b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta andor gamma isoforms of PI3K Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Infinity Pharmaceuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Exposure Probability Now

   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Infinity Pharmaceuti using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Infinity Pharmaceuti Correlation against competitors. Note that the Infinity Pharmaceuti information on this page should be used as a complementary analysis to other Infinity Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Infinity Stock analysis

When running Infinity Pharmaceuti price analysis, check to measure Infinity Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infinity Pharmaceuti is operating at the current time. Most of Infinity Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Infinity Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Infinity Pharmaceuti's price. Additionally, you may evaluate how the addition of Infinity Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Is Infinity Pharmaceuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Infinity Pharmaceuti. If investors know Infinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Infinity Pharmaceuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Infinity Pharmaceuti is measured differently than its book value, which is the value of Infinity that is recorded on the company's balance sheet. Investors also form their own opinion of Infinity Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Infinity Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Infinity Pharmaceuti's market value can be influenced by many factors that don't directly affect Infinity Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Infinity Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Infinity Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Infinity Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.